Plain-English translation of NCT06455410 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding a new immunotherapy medication called to standard chemotherapy works better than chemotherapy alone for treating advanced nasopharyngeal cancer. is a type of immune-boosting drug designed to help your body's immune system fight cancer cells. Half of participants will receive the medication combined with chemotherapy and radiation, while the other half will receive chemotherapy and radiation without the new medication.
Standard chemotherapy combined with radiation works well for advanced nasopharyngeal cancer, but doctors want to see if adding this immunotherapy medication can improve results even further. Recent studies suggest that using immune-boosting drugs before radiation may help the body's immune system work better against cancer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive three cycles of chemotherapy over about 9 weeks, with some participants also receiving the new immunotherapy medication during this time. After that, you'll undergo radiation therapy to your head and neck area over about 7 weeks, with additional chemotherapy given during the radiation phase. Throughout the trial, you'll have regular visits for blood tests, imaging scans, and check-ups to monitor how you're responding to treatment and watch for any side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China